Weekly paclitaxel with epirubicin as second-line therapy of metastatic breast cancer: Results of a clinical phase II study

Seminars in Oncology

Volumn 24, Issue 5 SUPPL. 17, 1997, Pages

  Kohler, U ^a   Olbricht, S S ^a   Fuechsel, G ^a   Kettner, E ^a   Richter, B ^a   Ridwelski, K ^a  

^a UNIVERSITY OF LEIPZIG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

EPIRUBICIN; PACLITAXEL;

ADULT; AGED; ALOPECIA; ANEMIA; BLOOD TOXICITY; BREAST CANCER; CANCER COMBINATION CHEMOTHERAPY; CLINICAL ARTICLE; CLINICAL TRIAL; CONFERENCE PAPER; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFICACY; DRUG POTENCY; DRUG TOLERABILITY; FEMALE; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; NEUTROPENIA; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; THROMBOCYTOPENIA;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; EPIRUBICIN; HUMANS; MIDDLE AGED; NEOPLASM METASTASIS; PACLITAXEL;

EID: 0030695854     PISSN: 00937754     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (13)